US Stock Market Move | AI will be used to develop weight loss drugs, and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has increased by nearly 2% against the trend.
On Friday, Novo Nordisk (NVO.US) defied the trend and rose nearly 2%, closing at $86.77.
On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose nearly 2% against the market trend, closing at $86.77 USD. In terms of news, the company and the U.S. technology company Valo Health recently announced their agreement to expand the scope of their collaboration to develop up to 11 drugs by 2023, utilizing human data and artificial intelligence (AI) to develop up to 20 new therapies for obesity, type 2 diabetes, and cardiovascular diseases.
Related Articles
CONSUN PHARMA (01681) spent 1.518 million Hong Kong dollars to repurchase 100,000 shares on October 24th.
BJ ENERGY INTL (00686) generated approximately 1925.33 million kilowatt hours of total electricity in the first three quarters.
On October 24th, Midea Group Co., Ltd (00300) spent 99.99 million yuan to repurchase 1.338 million A shares.
CONSUN PHARMA (01681) spent 1.518 million Hong Kong dollars to repurchase 100,000 shares on October 24th.
BJ ENERGY INTL (00686) generated approximately 1925.33 million kilowatt hours of total electricity in the first three quarters.
On October 24th, Midea Group Co., Ltd (00300) spent 99.99 million yuan to repurchase 1.338 million A shares.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
